[HTML][HTML] Lenacapavir: a first-in-class HIV-1 capsid inhibitor

H Dvory-Sobol, N Shaik, C Callebaut… - Current Opinion in HIV …, 2022 - journals.lww.com
Lenacapavir: a first-in-class HIV-1 capsid inhibitor : Current Opinion in HIV and AIDS
Lenacapavir: a first-in-class HIV-1 capsid inhibitor : Current Opinion in HIV and AIDS Log in or …

The prevalence of Frascati-criteria-based HIV-associated neurocognitive disorder (HAND) in HIV-infected adults: a systematic review and meta-analysis

J Wei, J Hou, B Su, T Jiang, C Guo, W Wang… - Frontiers in …, 2020 - frontiersin.org
Background: The HIV associated mortality is decreasing in most countries due to the
widespread use of antiretroviral therapy. However, HIV-associated neurocognitive disorder …

Life expectancy after 2015 of adults with HIV on long-term antiretroviral therapy in Europe and North America: a collaborative analysis of cohort studies

A Trickey, CA Sabin, G Burkholder, H Crane… - The Lancet …, 2023 - thelancet.com
Background The life expectancy of people with HIV taking antiretroviral therapy (ART) has
increased substantially over the past 25 years. Most previous studies of life expectancy were …

Mapping HIV prevalence in sub-Saharan Africa between 2000 and 2017

L Dwyer-Lindgren, MA Cork, A Sligar, KM Steuben… - Nature, 2019 - nature.com
HIV/AIDS is a leading cause of disease burden in sub-Saharan Africa. Existing evidence has
demonstrated that there is substantial local variation in the prevalence of HIV; however …

Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active …

SK Gupta, M Berhe, G Crofoot, P Benson… - The Lancet …, 2023 - thelancet.com
Background Antiretroviral agents with novel mechanisms and dosing intervals could expand
treatment options for people with HIV. Lenacapavir, an inhibitor of capsid protein that makes …

Inflammation, immune activation, and antiretroviral therapy in HIV

CO Hileman, NT Funderburg - Current Hiv/aids reports, 2017 - Springer
Abstract Purpose of Review This review focuses on the differential effects of contemporary
antiretrovirals on systemic inflammation as heightened immune activation is linked to …

Aging with HIV: increased risk of HIV comorbidities in older adults

RA Roomaney, B van Wyk… - International journal of …, 2022 - mdpi.com
With improved access to antiretroviral treatment (ART), adults with HIV live longer to reach
older age. The number of older adults living with HIV is increasing steadily, giving rise to a …

Optimizing treatment for adults with HIV/AIDS in China: successes over two decades and remaining challenges

W Cao, E Hsieh, T Li - Current HIV/AIDS Reports, 2020 - Springer
Abstract Purpose of Review The introduction of the National Free Antiretroviral Therapy
Program (NFATP) in 2003 by the China National Center for AIDS/STD Control and …

Artificial intelligence in nanomedicine

D Ho, P Wang, T Kee - Nanoscale Horizons, 2019 - pubs.rsc.org
The field of nanomedicine has made substantial strides in the areas of therapeutic and
diagnostic development. For example, nanoparticle-modified drug compounds and imaging …

Achieving the fourth 90: healthy aging for people living with HIV

TG Harris, M Rabkin, WM El-Sadr - Aids, 2018 - journals.lww.com
The availability of potent antiretroviral therapy (ART) has transformed the HIV epidemic,
changing HIV disease from a fatal illness to a chronic, manageable condition. In higher …